XOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery
April 27, 2016 09:00 ET
|
XOMA Corporation
BERKELEY, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has initiated its...
InSpark Technologies Appoints Diabetes Experts to Inaugural Thought Leadership Council
April 26, 2016 08:00 ET
|
InSpark Technologies
CHARLOTTESVILLE, Va., April 26, 2016 (GLOBE NEWSWIRE) -- InSpark Technologies, a leader in diabetes advanced pattern recognition technology, today announced the formation of its Thought Leadership...
New Vigilant™ Diabetes Management Companion Launched in U.S. That Alerts Users to Risk of Severe Hypoglycemia in Next 24 Hours
April 26, 2016 08:00 ET
|
InSpark Technologies
CHARLOTTESVILLE, Va., April 26, 2016 (GLOBE NEWSWIRE) -- InSpark Technologies, Inc., a leader in diabetes pattern recognition technology, today announced that VigilantTM1 is now available for...
XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting
April 04, 2016 09:00 ET
|
XOMA Corporation
BERKELEY, Calif., April 04, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the presentation of data from...
XOMA Reports Fourth Quarter and Full-Year 2015 Financial Results
March 09, 2016 16:01 ET
|
XOMA Corporation
BERKELEY, Calif., March 09, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today reported the completion of its...
Xeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD Meeting
February 04, 2016 10:22 ET
|
Xeris Pharmaceuticals, Inc.
Austin, TX, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) will present data from a human factors study with its G-PenTM glucagon auto-injector during the 9th International...
InSpark Technologies Presents Study Results Supporting the Utility of Its Hypo Risk Indicator at the Diabetes Technology Meeting
October 22, 2015 08:00 ET
|
InSpark Technologies
BETHESDA, Md., Oct. 22, 2015 (GLOBE NEWSWIRE) -- InSpark Technologies, Inc., a leader in diabetes pattern recognition technology, has announced it is presenting a poster at the Diabetes Technology...
Xeris Pharmaceuticals Presents Non-Aqueous Glucagon Stability Data at the American Diabetes Association 73nd Scientific Sessions
June 21, 2013 10:00 ET
|
Xeris Pharmaceuticals, Inc.
Austin, TX, June 21, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that it is
presenting at the American Diabetes Association 73nd Scientific
Sessions in Chicago, IL...
Xeris Pharmaceuticals Awarded Phase II Funding of NIH Fast -Track SBIR Grant to Advance Glucagon for the Artificial Pancreas
April 17, 2013 11:39 ET
|
Xeris Pharmaceuticals, Inc.
Austin, TX, April 17, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based,
pharmaceutical company developing patient-friendly injectable
treatments for diabetes and other...